SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing a massive wave of bullish sentiment as retail investors rally around a potential short squeeze, citing strong fundamentals, a consistent dividend, and a new leadership team as catalysts for a long-term revaluation. The community is actively coordinating to hold shares and force institutional shorts to cover, drawing comparisons to historic meme stock movements while emphasizing the company's solid business model.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging after reporting blowout quarterly earnings and providing guidance that shattered analyst expectations, driven by relentless demand for memory chips in AI data centers. The community is actively discussing a potential gamma squeeze and price discovery phase, with many investors debating whether the company has successfully decoupled from its historical cyclical patterns to enter a long-term AI-driven growth trajectory.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing intense volatility and downward pressure as sentiment shifts, with community debate sharply divided between those viewing the decline as a generational buying opportunity and others labeling it an overvalued bubble nearing a deeper breakdown. Investors are closely monitoring support levels and institutional activity while expressing frustration over the stock's disconnect from its recent performance, fueling active discussions regarding potential short squeezes versus further capitulation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is experiencing high volatility as investors react to its aggressive push into AI infrastructure, including a $4 billion acquisition of Modular and potential custom silicon partnerships, alongside its upcoming Investor Day. While the stock has faced sharp pullbacks following sector-wide sentiment shifts, the community is actively debating whether these strategic data center moves justify a significant long-term valuation re-rating.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as investors anticipate the final results of its Phase 3 REGAL trial, with the community actively speculating on the timing of the 80th event trigger. The stock is seeing high trading activity and elevated borrow fees, fueling intense debate between retail bulls who foresee a massive potential squeeze and bears skeptical of the trial's final outcome.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense investor pressure and heavy selling activity as market participants express frustration over high AI-related capital expenditures and a disconnect between the company's software performance and the broader semiconductor rally. While some traders view the current decline as a generational buying opportunity reminiscent of past tech cycles, the community remains deeply divided, with many actively hedging with puts amid fears of further downside and concerns regarding leadership strategy.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny as recent high-profile departures within its AI division fuel concerns about talent retention and structural momentum. While community sentiment remains divided, many investors are focused on the company's aggressive infrastructure spending and its strategic equity position in emerging leaders like SpaceX, weighing these long-term growth catalysts against near-term volatility.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is currently trending as investors focus on the official confirmation of a November launch for Grand Theft Auto VI, with community discussion centered on the impact of upcoming preorders and the potential for a transformative revenue cycle. While some retail traders remain cautious due to historical project delays and guidance concerns, many market participants are positioning for a long-term growth catalyst, noting that the title faces limited competition and maintains massive consumer anticipation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to significant retail speculation regarding potential acquisition or partnership activity, fueled by the launch of a new obesity drug trial and a recent surge in trading volume. The community is actively discussing the stock's position as a competitor to established obesity drug players and debating whether the firm should pursue a buyout or attempt to commercialize its pipeline independently.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors focus on upcoming clinical data catalysts and pivotal regulatory meetings, including an FDA advisory panel regarding its mRNA flu vaccine. The community remains divided between those capitalizing on institutional accumulation and momentum in the oncology pipeline, and those skeptical of the company's long-term profitability and historical stock volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EWTX Great post @Trainguy1.  Is it possible that we might actually be in the &quot;Buyer&quot; position now or lead a merger with $SRPT, $RGNX $SLBD?  I&#39;d mention $CAPR, but Linda has them on lockdown and looking for big money, not collab.   
 
Thoughts? 
 
Follow/Subscribe for more suggestions and perspective.  Would love to hear yours too.  That&#39;s how we find these gems and learn.  
  
Let&#39;s make some (more) money.  Cheers!

idea guy

Jeremy Jacob

George A Watson III

Jacqueline Turner

$EWTX  @S_Franconi  Based on all of this upward share price movement we&#39;ve been experiencing, I&#39;m starting to wonder if EWTX is considering a buy-out offer for the cardiac side of the company.  That would be a pretty good deal for the buyer: two heart therapeutics + about $3 billion cash for about $4.5 billion.  If my suspicion is true, then it&#39;s probable all they&#39;re waiting for are the upcoming results from the ph1 EDG-15400 trial.   I&#39;m good with an Edgewise acquisition.

StockTwits Web

Edgewise Therapeutics Inc

Trainguy1

Sarepta Therapeutics Inc

Regenxbio Inc

Capricor Therapeutics Inc

.  Is it possible that we might actually be in the "Buyer" position now or lead a merger with 

, but Linda has them on lockdown and looking for big money, not collab.   
 
Thoughts? 
 
Follow/Subscribe for more suggestions and perspective.  Would love to hear yours too.  That's how we find these gems and learn.  
  
Let's make some (more) money.  Cheers!

The Legendary Mayor

StockTwits for iOS

Gator

@BioRich @Trainguy1 Rich - Smartest move you&#39;ve made is staying out of SRPT. An utter disaster this stock / company is.

 Rich - Smartest move you've made is staying out of SRPT. An utter disaster this stock / company is.

Fred C.

@Fred_Sigma_Invest @Trainguy1 I love what they do for the patients, but my God, what a disaster of a stock.  Hate to see that because I know the product works.  Hopefully they can turn the corner, but I&#39;m not putting any money to that.  Biggest hope is they continue to supply to those in need because it does work.   
 
Ugh.  Hopefully you weren&#39;t hit too hard by them.   
 
Cheers!

 I love what they do for the patients, but my God, what a disaster of a stock.  Hate to see that because I know the product works.  Hopefully they can turn the corner, but I'm not putting any money to that.  Biggest hope is they continue to supply to those in need because it does work.   
 
Ugh.  Hopefully you weren't hit too hard by them.   
 
Cheers!

@BioRich @Trainguy1 It’s worse than what even the harshest bear could have predicted. I wouldn’t recommend SRPT to my worst enemy. The collateral damage has been widespread. I don’t think it will ever recover

 It’s worse than what even the harshest bear could have predicted. I wouldn’t recommend SRPT to my worst enemy. The collateral damage has been widespread. I don’t think it will ever recover

@Fred_Sigma_Invest @Trainguy1 That&#39;s unfortunately the feel that I get too.  Sad to see.

 That's unfortunately the feel that I get too.  Sad to see.

@BioRich @Trainguy1 @greko50 Yeah, and the level of delusion of people thinking this will turn around is mind blowing. It’s crazy what people will cling to when things are this bad.    
 
“Catalyst rich 2026” 
 
It’s crazy to see.

 Yeah, and the level of delusion of people thinking this will turn around is mind blowing. It’s crazy what people will cling to when things are this bad.    
 
“Catalyst rich 2026” 
 
It’s crazy to see.

@Gatorgunk @Trainguy1 Recent M&amp;A money, sitting on about a half billion in cash and a $4B MC.  But you make a good point, probably not buyers unless they do some financial gymnastics or raise, which we don&#39;t want...so disregard.  Was more looking at a merger of sorts.   
 
Not realistic though. Appreciate the input. 
Cheers!

 Recent M&A money, sitting on about a half billion in cash and a $4B MC.  But you make a good point, probably not buyers unless they do some financial gymnastics or raise, which we don't want...so disregard.  Was more looking at a merger of sorts.   
 
Not realistic though. Appreciate the input. 
Cheers!

@BioRich I don’t believe EWTX currently has a partner that performs a vital roll in the company, so that eliminates one theoretical EWTX  takeover target. I think EDG-7500 could become the standard of care for hypertrophic cardiomyopathy in a few years.  While they are working toward approval and building a customer base, I imagine they may test some combo therapies that include EDG-7500.  Maybe if they I.d. a combo drug that is compatible with 7500, they could consider an M&amp;A possibility.

 I don’t believe EWTX currently has a partner that performs a vital roll in the company, so that eliminates one theoretical EWTX  takeover target. I think EDG-7500 could become the standard of care for hypertrophic cardiomyopathy in a few years.  While they are working toward approval and building a customer base, I imagine they may test some combo therapies that include EDG-7500.  Maybe if they I.d. a combo drug that is compatible with 7500, they could consider an M&A possibility.

@Trainguy1 Great feedback, I appreciate this.  And it makes complete sense. Probably getting ahead of myself.  Will certainly look forward to potential combo options.  Always exciting to watch drug evolutions. 
 
Cheers! 
 
$EWTX

 Great feedback, I appreciate this.  And it makes complete sense. Probably getting ahead of myself.  Will certainly look forward to potential combo options.  Always exciting to watch drug evolutions. 
 
Cheers! 
 


@Fred_Sigma_Invest @Trainguy1 @greko50 Increasingly difficult on these boards.  Miss the old days.

 Increasingly difficult on these boards.  Miss the old days.